AVITA Medical amends PermeaDerm deal with Stedical, raising its revenue share to 67% and 80%
AVITA Medical signed a Global Amendment with Stedical Scientific dated August 5, 2026, changing their PermeaDerm distribution and manufacturing agreements. The company's revenue share rises to 67% for sheet-form products and 80% for glove-form products, and it gains a right of first offer on expanding its territory to parts of Europe, the UK, and Australia for a $500,000 fee.
Key points
- Company pays a $500,000 fee for a right of first offer and refusal on expanding exclusive distribution to all or part of the EU, UK, and/or Australia.
- Company's revenue share from PermeaDerm sales rises to 67% for sheet form and 80% for glove form, with revenue-sharing increases tied to gross margin thresholds of 50% and 35%.
- For 2026 the company must reach $1.0 million in total PermeaDerm revenue sharing payments, with 20% annual growth minimums through 2030; prior minimum payment requirements were waived.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.